M
Maxion Therapeutics
Ion channel and GPCR drug discovery using innovative KnotBody technology
About Maxion Therapeutics
Maxion Therapeutics is a biotechnology company specializing in the development of antibody-based drugs aimed at treating chronic pain, autoimmune disorders, and cardiovascular diseases. The company leverages its proprietary technology to target ion channels and G-protein-coupled receptors (GPCRs), which are implicated in a wide range of debilitating conditions. Unlike traditional small molecule drugs, Maxion's engineered antibodies offer superior selectivity and therapeutic efficacy, addressing the limitations of current treatments that often suffer from poor efficacy and side effects.
Maxion Therapeutics operates in the biopharmaceutical market, primarily serving healthcare providers and patients who are inadequately treated by existing medications. The company's business model revolves around research and development (R&D) of novel therapeutics, which are then advanced through clinical trials. Revenue is generated through partnerships, licensing agreements, and eventual commercialization of successful drug candidates.
The experienced leadership team, including co-founder and CSO Aneesh Karatt Vellatt and CEO Arndt Schottelius, brings a wealth of expertise from leading pharmaceutical companies and academic institutions. This strong foundation positions Maxion Therapeutics to make significant advancements in the field of antibody drug discovery.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Babraham, United Kingdom
- Employees
- 59
- Open positions
- 1
- Dealroom signal
- 91.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Hard Tech, proteomics, DT and LS, uk is8 life sciences, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Mar 2025 | $77M | $306M | British Business Bank · LifeArc Ventures · Business Growth Fund · Eli Lilly | ↗ |
| GRANTOther financing | Apr 2023 | $2.6M | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Maxion Therapeutics is 1.8K monthly website visits, down 52.6% over the last three months. Maxion Therapeutics's team grew 13.5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
LifeArc
Business Growth Fund
Monograph Capital
General Catalyst
British Business Bank
LifeArc Ventures
Eli Lilly
British Patient Capital
Solasta Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Maxion Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Maxion Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.